Forward Looking Statements

Statements herein the terms “believes”, “intends”, “projects”, “anticipates”, “expects”, and similar expressions as used are intended to reflect “forward-looking statements” of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the impact of the COVID-19 pandemic on our sales, operations and supply chain, the success of the Company’s global expansion initiatives and product diversification, the Company’s actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company’s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company’s business, the success of the Company’s initiative to expand its core business units to include biopharmaceutical manufacturing and operating clinics, the uncertainty of profitability from its biopharmaceutical manufacturing and operating clinics, the Company’s ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations, the success and enforceability of the Company’s umbilical cord blood and cord tissue license agreements, together with the associated intellectual property and their ability to provide the Company with royalty fees, and those risks and uncertainties contained in risk factors described in documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.
Cryo-Cell’s mission is to provide our clients with the premier cord blood and cord tissue cryopreservation services and to aid in the advancement of regenerative medicine.

Now Cryo-Cell can also treat patients.
The 2021 license agreement with Duke University transforms Cryo-Cell into an autonomous, vertically integrated cellular therapy company that will treat patients.
2021 Duke License Agreement Terms

• All Regulatory Data And Technical Information Related To 19 FDA Completed And Ongoing Clinical Trials - Includes 6 Completed Phase 2 Trials

• Rights to Intellectual Property And Proprietary Manufacturing Protocols Related To Cord Blood/Tissue Stem Cells To Treat Neurological Disorders Including Autism, Cerebral Palsy And Traumatic Brain Injuries

• "Methods for the treatment of autism spectrum disorders," U.S. Patent No. 10,912,801 was just granted in February, 2021

2021 Duke License Agreement Terms

• Right To Operate Cord Blood/Tissue Infusion Clinics Under FDA-Approved INDs
• Rights To Intellectual Property And Proprietary Manufacturing Protocols Related To DUOC\(^1\) To Treat Demyelinating Conditions Including Multiple Sclerosis
• All Rights Are Exclusive And Worldwide With Sublicensing Rights (Excluding Taiwan)
Duke Equity Milestones

➢ 5.0% of CCEL common stock granted at license execution

➢ 2.5% of CCEL common stock upon cumulative net sales of licensed product/process of $10 million

➢ 2.5% of CCEL common stock upon cumulative net sales of licensed product/process of $75 million

➢ 2.5% of CCEL common stock upon market cap $\geq$ $300$ million provided such trigger occurs by August 23$^{rd}$, 2022

➢ 2.5% of CCEL common stock upon market cap $\geq$ $500$ million provided such trigger occurs by February 23$^{rd}$, 2023
Clinical Trials Under FDA-Approved INDs

- Acquired Brain Injuries
- Adult Stroke
- Autism
- Cerebral Palsy
- Congenital Hydrocephalus
- COVID-19 Acute Respiratory Distress Syndrome
- COVID-19 associated Multisystem Inflammatory Syndrome in Children
- Hypoxic Ischemic Encephalopathy
- Leukodystrophies
- Multiple Sclerosis
- Osteoarthritis*

* Osteoarthritits of the Knee (IND for MILES study held by Emory University)
Cord Blood Industry Visionary

- Dr. Kurtzberg, Duke’s internationally renowned expert in cellular therapies and regenerative medicine, performed the first cord blood transplant in 1988.
- Since 2018, Dr. Kurtzberg has served as Cryo-Cell’s Medical Director.
- Dr. Kurtzberg has treated over 1,300 patients in clinical trials under FDA\(^1\)-approved INDs\(^2\) for cellular therapy, which is more than any other doctor in the world, as of March 2021.

\(^1\) FDA: Food & Drug Administration  \(^2\) IND: Investigational New Drug
HELPING AND HEALING

Click here to start the video
The Triad

CORD BLOOD & CORD TISSUE STEM CELL BANKING PRIVATE & PUBLIC DONATIONS

CELLULAR THERAPIES PHARMACEUTICAL MANUFACTURER

INFUSION CLINICS TO ADMINISTER CELLULAR THERAPIES UNDER FDA-APPROVED INDs
Cord Blood & Tissue
Stem cell banking
Incorporated in 1989, Cryo-Cell International is the world's first private cord blood bank.

In 2011, current leadership took over the day-to-day operations and transformed a company with declining market share into the leading cord blood bank. Management has a significant economic interest in the Company’s success, having invested millions of dollars of their own capital.
CORD BLOOD & TISSUE
STEM CELL BANKING

Worldwide
More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their baby’s cord blood and cord tissue stem cells.

Top Accreditations
Cryo-Cell was the first private-only cord blood bank in the USA to receive both FACT\(^1\) and AABB\(^2\) accreditation.

Leading Technology
Cryo-Cell owns the exclusive rights to PrepaCyte-CB, the industry’s most advanced cord blood processing technology.

---

\(^1\) FACT: Foundation for the Accreditation of Cellular Therapy \(^2\) AABB: American Association of Blood Banks
Cash flow has grown steadily since 2011, and the Company now generates over $8 million per year.
Cord Blood & Tissue
Stem Cell Banking

Cryo-Cell Total Revenues

Year


Total Revenues

$40,000,000

$30,000,000

$20,000,000

$10,000,000

$0

Cryo-Cell International
CORD BLOOD & TISSUE STEM CELL BANKING

- Annual recurring revenues from stored stem cell specimens are in excess of $18 million per year.

- This annuity stream has increased every year since the Company’s inception and the customer retention rate is exceptionally high.
CORD BLOOD & TISSUE STEM CELL BANKING

Fiscal year ending 11/30/2020:

➢ Revenues = $31.1 million
➢ Net income = $3.62 million
➢ Fully diluted earnings per share = $0.45
➢ Cash flow from operations = $8.5 million
CORD BLOOD & TISSUE STEM CELL BANKING

As of 02/28/2021:

➢ Cash & marketable securities = $11.4 million
➢ Total debt = $4.2 million
➢ Total shares repurchased = 6.1 million shares at an average price of $3.37 per share
**Valuation Gap**

The following shows the market capitalization of Cryo-Cell as compared to the market capitalization investors are placing on pure play cellular therapy companies which have only one of the three Cryo-Cell business units.

<table>
<thead>
<tr>
<th>Companies</th>
<th>Market Cap (as of 08/13/2021)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MESO – Mesoblast Ltd.</td>
<td>$944 million</td>
</tr>
<tr>
<td>ATHX – Athersys Inc.</td>
<td>$364 million</td>
</tr>
<tr>
<td>BCLI - Brainstorm Cell Therapeutics Inc.</td>
<td>$129 million</td>
</tr>
<tr>
<td>PSTI - Pluristem Therapeutics Inc.</td>
<td>$99 million</td>
</tr>
<tr>
<td>CCEL – Cryo-Cell International, Inc.</td>
<td>$78 million</td>
</tr>
</tbody>
</table>
Competitive Advantage
Control over all aspects of the treatment

CORD BLOOD & TISSUE
STEM CELL BANKING
PRIVATE &
PUBLIC DONATIONS

Sourcing

ProducIng

Infusing

CELLULAR
THERAPIES
PHARMACEUTICAL
MANUFACTURER

INFUSION CLINICS TO
ADMINISTER CELLULAR
THERAPIES UNDER
FDA-APPROVED INDs

CryoCell
INTERNATIONAL
Infusion clinics to administer cellular therapies under FDA-approved INDs
Cryo-Cell Intends To Open An Infusion Clinic(s) To Administer Cellular Therapies Under FDA-Approved INDs To Treat Patients With CP, Autism, And Traumatic Brain Injuries
INFUSION CLINIC TO ADMINISTER CELLULAR THERAPIES UNDER FDA-APPROVED INDs

Estimated infusion revenue per patient per treatment of $15,000

Approximate new U.S. diagnosed cases per year:
- Children with autism 60,000
- Children with cerebral palsy 10,000
- Children with traumatic brain injury 50,000

Annual revenue per clinic is projected to be $24 million.
CELL THERAPY
PHARMACEUTICAL
MANUFACTURER

CryoCell International
Full regulatory compliance.

Strong safety profile already established.

Proprietary cell culture and expansion protocols in place with additional ongoing optimization.

Characterization assays established; Potency assays in development.

Projected 2023 production capacity of 10,000 doses.

Preemptively overcoming challenges surrounding scalability and consistency of raw materials by securing reliable supply of GMP-compliant raw materials for timely development of successful cell therapies.
<table>
<thead>
<tr>
<th>Mechanism of Action</th>
<th>Autologous Cord Blood Cells</th>
<th>Allogeneic Cord Blood Cells</th>
<th>DUOC-01</th>
<th>Allogeneic Cord Tissue MSCs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduce Inflammation</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Reduce CNS Inflammation</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Promote Oligodendrocyte Proliferation</td>
<td>?</td>
<td>?</td>
<td>✓</td>
<td>?</td>
</tr>
<tr>
<td>Modulate Brain connectivity</td>
<td>✓</td>
<td>✓</td>
<td>?</td>
<td>✓</td>
</tr>
<tr>
<td>Rescue for Hypoxia</td>
<td>✓</td>
<td>✓</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>Promote Remyelination</td>
<td>?</td>
<td>?</td>
<td>✓</td>
<td>?</td>
</tr>
</tbody>
</table>

**Indications under current clinical study**
- HIE, Stroke, CP, Autism
- HIE, Stroke, CP, Autism
- Leukodystrophies MS
- HIE, CP, OA Autism, Covid
## Pipeline of Select INDs

**RPC:** Randomized Placebo Controlled study

### Cell Therapy Pharmaceutical Manufacturer

<table>
<thead>
<tr>
<th>Indication</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Study Name/Read out</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Autologous Cord Blood</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autism</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Duke ABC Phase 1</td>
</tr>
<tr>
<td>CP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Duke ACT Phase 2</td>
</tr>
<tr>
<td>HIE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CP – AC Phase 1</td>
</tr>
<tr>
<td><strong>Allogeneic Cord Blood</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autism</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CP Sibling Phase 1</td>
</tr>
<tr>
<td>CP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AcceNT-CP Phase 2</td>
</tr>
<tr>
<td>Stroke</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CoBIS I Phase 1</td>
</tr>
<tr>
<td><strong>DUOC-01</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukodystrophies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Duke ACT Phase 2</td>
</tr>
<tr>
<td>MS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CoBIS II Phase 2</td>
</tr>
<tr>
<td><strong>Cord Tissue MSCs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autism - Children</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>hCT - MSC IMPACT</td>
</tr>
<tr>
<td>Autism – Other Age Groups</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TACT/4Q2022 (Toddlers) AIMS /4Q2022 (Adults)</td>
</tr>
<tr>
<td>HIE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>hCT-MSC HIE</td>
</tr>
<tr>
<td>COVID 19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ARDS: MASC Phase 1</td>
</tr>
</tbody>
</table>

**Notes:**
- **RPC:** Randomized Placebo Controlled study.
The Marcus Center for Cellular Cures (MC3) at Duke University School of Medicine has been established to bring together physicians and faculty across medicine and engineering at Duke to develop cellular and biological therapies for autism, cerebral palsy, stroke, multiple sclerosis and related brain disorders.

The MC3 proudly hosts an impressive numbers of team members:
- 19 PhDs
- 14 MDs
- 70 Researchers
- 22 Clinicians (Includes MDs, NPs and NCs)

With over 1,300 patients treated under FDA-approved IND cellular therapy trials in the last 10 years

*Osteoarthritis of the Knee (IND for MILES study held by Emory University)*
CELL THERAPY PHARMACEUTICAL MANUFACTURER

Market Size
(# affected patients in the USA)

- HIE: 6 Thousand
- CP: 0.8 Million
- ASD: 3.5 Million
- Stroke: 6 Million
- OA: 30 Million

Market Size Therapeutic Applications
CELL THERAPY PHARMACEUTICAL MANUFACTURER

Autism Spectrum Disorders (ASD)

TACA

PROJECTED COST TO SOCIETY BY 2025 TO REACH $1 TRILLION ANNUALY
Autism Spectrum Disorders (ASD)

- **Study Name: Duke ACT**\(^1\) [NCT02847182]
- PHASE 2 randomized and controlled study on autologous and HLA-matched allogeneic cord blood infusion for children with autism spectrum disorder.
- Enrollment for this study has been completed with a sample size of 180 patients.
- Infusion for children with ASD proved to be safe and well tolerated.

\(^1\) [https://www.sciencedirect.com/science/article/pii/S0022347620303346](https://www.sciencedirect.com/science/article/pii/S0022347620303346)
Autism Spectrum Disorders (ASD)

**Study Name: Duke ACT**\(^1\) [NCT02847182]

- In a sub-analysis of children without intellectual disability (IQ>70), children treated with cord blood stem cells showed significant improvements in communication skills and exploratory measures including attention to toys and executive function on eye tracking, and increased alpha and beta electroencephalographic power.

- MRI results under analysis.

- The study did not meet its primary endpoint; target enrollment for children without intellectual disability fell short (101 instead of 143); the placebo effect was larger than expected in parent reported outcomes.

Autism Spectrum Disorders (ASD)

- **PHASE 1** Studies of HCT-MSC, An Umbilical Cord-Derived Mesenchymal Stromal Cell Product:
  - In **Adults** with ASD
  - In **Children** with ASD
  - In **Young Children**
  - Read out expected 4Q2022 for AIMS and TACT
  - Results on the hCT-MSC infusions were safe - 58% of the study participants showed improvement on 2 or 3 of the 3 outcome measures tracked

- **PHASE 2** Ongoing Randomized and Controlled Study of HCT-MSC, An Umbilical Cord-Derived Mesenchymal Stromal Cell Product, In Children With Autism
  - **IMPACT** [NCT04089579]
  - Read out expected 4Q2022

1 HCT-MSC: HUMAN UMBILICAL CORD TISSUE-DERIVED MESENCHYMAL STROMAL CELLS
Cerebral Palsy (CP)

**Study Name: CP-AC**¹ [NCT01147653]
- Autologous CBU – Phase 2 randomized, blinded, placebo-controlled, crossover study completed to find out if autologous umbilical cord blood infusion were beneficial in children with cerebral palsy.
- Sample size 63.
- Results suggest that adequately dosed intravenous infusion of autologous umbilical cord blood improves motor function and whole brain connectivity in the motor tracks of young children with CP.

Sun, Jessica; Kurtzberg, Joanne, et al. Effect of Autologous Cord Blood Infusion on Motor Function and Brain Connectivity in Young Children with Cerebral Palsy: A Randomized, Placebo-Controlled Trial. Stem Cell translational Medicine. 28 October 2017
Cerebral Palsy (CP)

**Study Name: CP Sibling**\(^1\) [NCT02599207]
- Allogeneic CBU – Phase 1/2 completed [HLA-matched sibling donors\(^2\)] sample size 15.
- Assessment of the safety of allogeneic umbilical cord blood infusions in children with CP.
- IV infusion of sibling cord blood at an effective cell dose is safe and well tolerated.
- Improvement of motor function duplicated results of the CP-AC study.

**Study Name: AcceNT-CP**\(^3\) [NCT03473301]
- Allogeneic CBU & hCT-MSC – Phase 2 randomized placebo-controlled study completed.
- Sample size 90.
- Preliminary results reveal a statistically significant improvement in motor function for the allogeneic cord blood arm but not for the MSC arm, comparing each to a natural history (control arm).

---

\(^1\) [https://doi.org/10.1002/sctm.20-0470] “Sibling umbilical cord blood infusion is safe in young children with cerebral palsy” Jessica M. Sun, Laura E. Case, Mohamad A. Mikati, Joan M. Jasien, Colleen McAulghlin, Barbara Waters-Pick, Gordon Worley, Jesse Troy, Joanne Kurtzberg.

\(^2\) Six children received cord blood cells from an HLA-matched sibling and 9 children received cord blood cells from a haplo-identical sibling.

\(^3\) Manuscript in preparation, soon to be published in the next edition of Developmental Medicine & Child Neurology Journal.
Hypoxic Ischemic Encephalopathy (HIE)

**Study Name: BabyBac**¹ [NCT00593242]
- Autologous CBU – Phase 1 completed. Sample size 23.
- Assessment of the feasibility and safety of autologous cord blood cells for HIE.
- Results show that collection, preparation, and infusion of fresh autologous cord blood for use in infants with HIE is feasible.
- 74% of the cell recipients with known 1-year outcomes survived with scores >85, compared to 41% of a concurrent group of cooled infants (p=0.04).

**Study Name: BabyBacII**² [NCT02612155]
- Autologous CBU – Multi-Site Phase 2 randomized and controlled study for HIE.
- Enrollment terminated due to logistical difficulties of collecting cord blood during a distress birth.
- Preliminary analysis of the results of the 37 enrolled and randomized patients were positive (p=0.06).
- Off-the-shelf hCT-MSCs were explored in a 6 patient phase 1 study and results were positive. Combined, these results support the move to the next study using hCT-MSC to provide access to the cell therapy product for all babies.

¹ HTTPS://WWW.SCIENCEDIRECT.COM/SCIENCE/ARTICLE/PII/S0022347613014716
² HTTPS://PLAN.CORE-APPS.COM/PAS2020/ABSTRACT/6EDEC56C63F592ADB37F205EAA93C4FBE
Study Name: hCT-MSC HIE\(^1\) [NCT03635450]

- hCT-MSC – Phase 1 completed for the study of hCT-MSC, an umbilical cord-derived mesenchymal stromal cell product, in newborn infants with moderate or severe hypoxic ischemic neonatal encephalopathy. Sample size 6.
- Results show that hCT-MSC can be infused safely in infants treated with hypothermia for moderate to severe HIE.
- One dose was given in the first 48 hours of life and the second dose (in 2 patients) at 2 months of age.
- All children treated are alive.
- Hospital discharge was 9-10 days.
- MRIs were normal at 9 days of age.

\(^1\)https://www.sciencedirect.com/science/article/pii/S146532492030579X
COTTEN, CM; SIMMONS, R ET AL. PHASE I TRIAL OF ALLOGENEIC UMBILICAL CORD TISSUE-DERIVED MESENCHYMAL STROMAL CELLS IN NEONATES WITH HYPOXIC-ISCHEMIC ENCEPHALOPATHY. CYTOTHERAPY VOLUME 22, ISSUE 5, SUPPLEMENT MAY 2020
Multiple Sclerosis (MS) and Demyelination Disorders

**Study Name: DUOC-MS**

- DUOC-01 - Phase 1 Enrollment starting soon. Sample Size 20.
- Trial of Intrathecal Administration of Human Umbilical Cord Blood-Derived Cell Therapy (DUOC-01) in Adults with Progressive Multiple Sclerosis (MS).
- Read out expected 4Q 2023.
- $5 million funding provided by The Marcus Foundation.
COVID 19 Acute Respiratory Distress Syndrome (ARDS)

**Study Name: MASC** [NCT04399889]
- hCT-MSC – Phase 1/2 Ongoing. Sample Size 50
- Pilot Randomized and Controlled study of Safety and Efficacy of Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC) in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS).
- First 10 patients is straight Phase 1 (no randomization, no placebo).
- Next 40 patients is Phase 2 randomized blinded, Placebo- controlled trial 2:1:1 using cells manufactured at Duke or at the U Miami.
- Read out expected 2Q2022.
Executive Team

David I. Portnoy,
Chairman of the Board and Co-CEO

Mr. Portnoy has served as Chairman of the Board and Co-Chief Executive Officer of the Company since August 2011.

Since 2002, Mr. Portnoy has served as Chairman of the Board of Directors of Partner Community, Inc., which provides B2B integrations between telecommunication service providers, such as Verizon Communications Inc., and their largest enterprise customers.

Mr. Portnoy’s venture capital company lead early-stage investment rounds in Waves Audio Ltd, the world’s leading developer of audio plugins and signal processors for the professional and consumer electronics audio markets with customers that include DELL, ASUS, JVC, NEC, Denon, and Oppo. Heard on hit records, major motion pictures, and popular video games worldwide, Waves’ cutting-edge software and hardware processors are used in every aspect of audio production, from tracking to mixing to mastering, broadcast, live sound, and more.

Mr. Portnoy has been an advocate of blockchain technology and cryptocurrencies, having first purchased bitcoin in early 2012.

Mr. Portnoy graduated Magna Cum Laude in 1984 from The Wharton School of Finance at the University of Pennsylvania.
Mark L. Portnoy, Co-CEO

Mr. Portnoy has served as a Director and Co-Chief Executive Officer since August 2011. During this time, he has helped lead Cryo-Cell to establish a national sales force in 2012, adopt Prepacyte-CB, the most advanced cord blood processing system, in 2014 and acquire the exclusive worldwide rights to it in 2016 and purchase Cord:Use Cord Blood Bank, thereby entering the public cord blood banking industry in 2018.

Additionally, since 2002 and 2007, Mr. Portnoy has served on the boards of directors of Partner-Community, Inc. and uTIPu Inc., a private Internet-based business, respectively.

Mr. Portnoy has been engaged in managing his personal investments since April 1997. From January 1995 to April 1997, Mr. Portnoy was employed at Strome, Susskind Investments as its Chief Fixed Income Trader.

From March 1986 until November 1991, Mr. Portnoy was employed at Donaldson, Lufkin & Jenrette Securities Corp. as a Fixed Income Arbitrage Trader, with a trading portfolio ranging in size from $1 billion to $7 billion.

Mr. Portnoy graduated Phi Beta Kappa from the University of North Carolina at Chapel Hill with a degree in Economics in December 1985.
EXECUTIVE TEAM

Joanne Kurtzberg, M.D. Medical Director

Jerome Harris Distinguished Professor of Pediatrics Professor of Pathology
Director, Marcus Center for Cellular Cures
Director, Pediatric Blood and Marrow Transplant Program
Director, Carolinas Cord Blood Bank
Co-Director, Stem Cell Transplant Laboratory Duke University Medical Center

Dr. Kurtzberg is a pioneer in the cord blood field, performing the first unrelated cord blood stem cell transplant, in 1993.

She is an internationally renowned expert in pediatric hematology-oncology, pediatric blood and marrow transplantation, umbilical cord blood banking and transplantation, and the novel application of cord blood in the emerging fields of cellular therapy and regenerative medicine.

Dr. Kurtzberg was awarded a lifetime achievement award from the PBMTC in 2012. She is the President of the Cord Blood Association. She previously served on the board of the Foundation for the Accreditation of Cellular Therapies and currently co-chairs their cord blood banking standards committee. She co-chairs the National Marrow Donor Program’s Cord Blood Advisory Group and is a past member of the Advisory Council for Blood Stem Cell Transplantation reporting to the Director of Health and Human Services. She is the Director of the Marcus Center for Cellular Cures at the Duke University School of Medicine.

She served as an advisor on the Oncologic Drugs Advisory Committee (ODAC) meeting held for Mesoblast, Inc. in 2020.
Executive Team

Oleg Mikulinsky, CIO

Mr. Mikulinsky has served as Cryo-Cell’s Chief Information Officer since March 2012.

Mr. Mikulinsky is a software technologist and serial entrepreneur. He has been a founding member of several software enterprises and most recently served as Chief Technology Officer of Partner-Community, Inc and Chief Technology Officer at uTIPu Inc. from 2007 to 2009.

Mr. Mikulinsky served as the Director of Enterprise Architecture at WebLayers, Inc. where he defined enterprise architecture best practices for companies like AT&T, Defense Information Systems Agency (DISA), as well as for many major banking institutions.

He contributed to the development of International systems interoperability standards at OASIS-OPEN.ORG and WS-I.ORG.

Prior to starting his professional career as a software engineer in the United States, Mr. Mikulinsky studied radio electronics at the Bauman Moscow State Technical University (BMSTU), Russia.
Executive Team

Jill Taymans, Chief Financial Officer

Ms. Taymans has served as the Company’s Chief Financial Officer since 1998.
Prior to joining the Company, she served for three years as Controller for a telecommunications company.
Ms. Taymans has worked as an accountant in both the public and private sectors for over 30 years.
Ms. Taymans graduated from the University of Maryland in 1991 with a BS in Accounting.
Todd Schuesler, BS, MBA
Director of Laboratory Operations

Mr. Schuesler is responsible for the state-of-the-art laboratory, process improvements and research at Cryo-Cell. He also oversees PrepaCyte-CB, a 510K product which Cryo-Cell manufactures for internal use and for a select group of cord blood laboratories.

Previously, Mr. Schuesler has held positions in molecular, gene and cellular therapies. While at Cincinnati Children’s Hospital he helped establish the Translational Trials Development and Support Lab and was part of the team that brought the first gene therapy clinical trial to the hospital. In addition, he was the manager of the Cellular Therapies Division of Hoxworth Blood Center at University of Cincinnati where his lab provided cell processing and storage services to nearly half of the marrow transplant centers in Ohio and developed the first Cytotoxic T-Cell immunotherapy product offered at Cincinnati Children’s Hospital as well as supported the pancreatic islet transplant program at the University of Cincinnati.

Mr. Schuesler holds a Bachelor of Science in Biology from Bowling Green State University, and a Masters of Business Administration from the University of Scranton. He also volunteers as an auditor for the AABB.
Andrea Darrow, Senior Quality Assurance and Regulatory Manager

Ms. Darrow joined Cryo-Cell in 2014 to ensure compliance to the quality, regulatory and accreditation requirements for cellular therapy and medical device products.

Prior to joining Cryo-Cell, Ms. Darrow was the Director of Quality Assurance and Regulatory for cellular therapy at the Hoxworth Blood Center at the University of Cincinnati.

Ms. Darrow, began her career in quality as a Quality Assurance Compliance Associate at a growing sterile injectable pharmaceutical company, building the non-conformance systems and establishing the training program.

Prior thereto, Ms. Darrow served as a Research Assistant at the College of Cell and Neurobiology studying how molecules regulate the effect on neural stem cells.

Ms. Darrow earned her Master of Science from the University of Cincinnati and her Bachelor of Science in Biotechnology from Rochester Institute of Technology.
Executive Team

Thomas Moss  
Director of Infusion Services

Mr. Moss is responsible for the development and implementation of Cryo-Cell’s planned infusion clinic(s).

Mr. Moss comes to Cryo-Cell after a long career in both blood and cord blood banking. Most recently, he was the Director of the LifeSouth Cord Blood Bank, which is a non-profit bank that manufactures an FDA licensed cord blood drug product. Prior to that, Mr. Moss was the Vice President of CORD:USE Cord Blood Bank, which he helped create. He was responsible for the oversight of all aspects of both public and private banking operations.

Additionally, he previously served as the Director of Operations for the cord blood program of the New York Blood Center, which is the largest public cord blood bank in the world. Prior thereto, Mr. Moss managed all laboratory operations and implemented lean manufacturing production techniques at Viacord. Mr. Moss started his career at the Hoxworth Blood Center of the University of Cincinnati.

Mr. Moss is very experienced in creating and maintaining efficient, high-quality operations in heavily regulated environments. He received a BS in Industrial Engineering from Marietta College.
Our VISION

Our PLATFORM

Your OPPORTUNITY

- CB Bank
- Infusion Clinics
- Clinical Trials and Manufacturing
  - CORD BLOOD
    - Conduct Phase 3 trials in CP & ASD
    - Expand indications under current BLA
    - File BLAs and obtain approvals
    - Potential indications: HIE, CP, ASD, Stroke
  - CORD TISSUE MSCs
    - Complete IMPACT ASD Phase 2 trial (funded MF)
    - Upscale manufacturing
    - Conduct Phase 3 registration trial
    - File BLAs and obtain approvals
    - Potential indications: HIE, CP, ASD, OA
  - DUOC
    - Conduct Phase 2/3 trials in adults with MS
    - Optimize manufacturing

1 BLA: Biologics License Application